Louisiana Launches Hepatitis C Innovative Payment Model With Asegua Therapeutics, Aiming to Eliminate the Disease
Today, Governor John Bel Edwards joined Secretary Rebekah Gee of the Louisiana Department of Health, Secretary James LeBlanc of the Louisiana Department of Corrections, and Asegua Therapeutics LLC, a wholly-owned subsidiary of Gilead Sciences, Inc. (Nasdaq: GILD), to announce a deal that will allow the implementation of an innovative payment model for hepatitis C treatment, part of Louisiana’s plan to eliminate the disease.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190626005539/en/
“This new model has the potential to save many lives and improve the health of our citizens. It is an important day for our state, for our partner Asegua Therapeutics, for providers, but most importantly for the patients and their families who will benefit from treatment,” said Governor Edwards. “Asegua was willing to come to the table to work with us to help Louisiana residents and we are pleased to initiate this five year partnership. Ultimately, our goal is to eliminate this disease in Louisiana, and we have taken a big step forward in that effort.”
In the United States, hepatitis C kills more people than all other infectious diseases combined. At least 39,000 people in Louisiana's Medicaid program and prison system suffer from hepatitis C infection.
“An elimination plan and innovative payment model will ensure that we can cure this deadly disease and prevent long-term illness and disability in those who have it,” said Dr. Rebekah Gee, secretary of the Louisiana Department of Health. “The Department of Health’s goal is to treat at least 31,000 people by the end of 2024 and eventually eliminate this disease.”
After extensive research and work with policy experts across the nation, the Department of Health released a solicitation of offers in January of 2019 in search of a pharmaceutical company willing to partner with Louisiana on a subscription model. Asegua Therapeutics was announced as the selected partner in April, and through subsequent discussions the parties have agreed to a modified model.
“We are pleased that Asegua has the courage to be a pioneer and chart a new path forward that will allow us to save many lives and improve the health of our citizens,” added Gee.
The innovative payment model for Louisiana addresses the needs of patients and joins the goals of both Louisiana and Asegua to extend a cure to those in need.
“This partnership will have a direct and immediate impact on the most vulnerable populations with hepatitis C – people who are on Medicaid or who receive care through the state corrections system. These populations are disproportionately affected by hepatitis C and often face the greatest difficulty in accessing care,” said Gregg Alton, Chief Patient Officer at Gilead Sciences. “We are committed to supporting efforts to eliminate hepatitis C in communities around the world and are excited to partner with the visionary leaders in Louisiana to make this public health opportunity a reality in this state.”
The innovative payment model allows the state to purchase an unlimited amount of Asegua’s direct-acting antiviral medication, the authorized generic of Epclusa® (sofosbuvir/velpatasvir) to treat patients within Louisiana’s Medicaid and Department of Corrections populations and caps the State’s medication costs.
“With this model to purchase hepatitis C medications, we can cure those within the state facilities who have this life-threatening illness and prevent the spread of the illness within our facilities,” said James LeBlanc, secretary of the Louisiana Department of Corrections. “We will also work closely with the Department of Health to implement a plan to screen and treat the local level population either while incarcerated or upon release into supervision. Most importantly, we can make sure these men and women have an opportunity to be even more successful and healthy when they return to their communities.”
The Department of Health and Asegua completed and signed a formal contract for the purchase of Asegua’s hepatitis C medication, the authorized generic of Epclusa, over five years, and for people enrolled in the Medicaid program and incarcerated people in Louisiana. The Department of Health continues to implement an elimination plan that engages partners across the state to educate the public on the availability of a cure and reach out to high-risk populations for screenings; connect people living with hepatitis C to care; expand provider capacity; and establish partnership across the state to eliminate hepatitis C in Louisiana.
About Louisiana Department of Health
The Louisiana Department of Health strives to protect and promote health statewide and to ensure access to medical, preventive and rehabilitative services for all state residents. The Louisiana Department of Health includes the Office of Public Health, Office of Aging & Adult Services, Office of Behavioral Health, Office for Citizens with Developmental Disabilities, and Healthy Louisiana (Medicaid). To learn visit www.ldh.la.gov or follow us on Twitter, Facebook, or our blog.
About Asegua Therapeutics
Asegua Therapeutics is a wholly-owned subsidiary of Gilead Sciences, Inc. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. For more information on Gilead Sciences, please visit the company’s website at www.gilead.com.
This press release includes forward-looking statements related to Asegua Therapeutics, a subsidiary of Gilead Sciences, Inc., within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties not may not realize the potential benefits of this partnership. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2019, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.
ASEGUA and the ASEGUA logo are trademarks of Asegua Therapeutics LLC. EPCLUSA and GILEAD are trademarks of Gilead Sciences, Inc. or its related companies.
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Louisiana Department of Health Contact:
Kelly Zimmerman, Media
Sung Lee, Gilead Investors
Sonia Choi, Media
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Expands in India With Membership of Nangia Andersen LLP17.10.2019 16:30:00 EEST | Press release
Andersen Global continues to expand its footprint in the East, announcing the addition of a new member firm in India, Nangia Andersen LLP. Andersen Global debuted in India over a year ago when Nangia Advisors LLP signed a collaborating agreement with the international association. The firm, one of the largest in India, has 350+ professionals in numerous office locations throughout the country, including Noida, New Delhi, Mumbai, Gurugram, Bengaluru, Pune, Chennai and Dehradun. For nearly 38 years, the firm has provided services to multinational companies with India interests in entry strategy, re-organizations, cross-border taxation, transfer pricing, tax consulting and advising, tax litigation, mergers & acquisitions, GST and investment banking across a broad range of sectors. “Andersen Global and Nangia Andersen LLP match in terms of values and commitment to transparency, high ethical standards, technical accuracy and quality service to clients. We found immediate synergy with the pr
Mavenir Confirmed as Global Leader in NFV-based IMS Solutions17.10.2019 16:00:00 EEST | Press release
Mavenir, the industry's only end-to-end cloud-native 4G and 5G network software provider for CSPs, has been ranked #1 among the Top 5 vendors in NFV VoLTE/IMS, in a recent Dell’Oro Group report1 in both Licenses and Revenue metrics. In cumulative worldwide NFV licenses, Mavenir boasts more than the next 2 vendors combined, according to the report. Mavenir’s leadership in NFV IMS is evident by the number of new IMS network wins. Just in the last 9 months, Mavenir has been selected to replace 8 legacy networks in Tier 1 Operators in key regions around the world, taking market share from the legacy vendors. Mavenir’s consistent software only (HW agnostic) focus has accelerated NFV market momentum, while legacy vendors have been slow to move away from proprietary hardware-based offerings. As an early adopter and entrant into virtualized solutions, Mavenir gained tremendous experience and expertise in large scale deployments across all regions and with various network infrastructures and to
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with HER2 Positive Metastatic Breast Cancer17.10.2019 14:00:00 EEST | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for [fam-] trastuzumab deruxtecan (DS-8201) and granted Priority Review. The Prescription Drug User Fee Act (PDUFA) date for [fam-] trastuzumab deruxtecan, an investigational HER2 targeting antibody drug conjugate (ADC), for the treatment of patients with HER2 positive metastatic breast cancer is set for the first quarter of fiscal year 2020. “We are pleased that the FDA has accepted the application and granted Priority Review as we believe [fam-] trastuzumab deruxtecan has the potential to redefine the treatment of patients with HER2 positive metastatic breast cancer,” said Antoine Yver, MD, MSc, Executive Vice President and Global Head, Oncology Research and Development, Daiichi Sankyo. “Following the recent regulatory submission in Japan, we look forward to working closely with reg
Mobile Game Ragnarok M: Eternal Love Officially Launches in Europe and Russian Region on October 16th17.10.2019 13:50:00 EEST | Press release
On October 16th Gravity Interactive, Inc., a subsidiary of Gravity Co., Ltd. (NASDAQ:GRVY) which is a leading global game company, announced that it launched its mobile game Ragnarok M: Eternal Love in Europe and Russian regions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005400/en/ Gravity Interactive, a subsidiary of Gravity Co., Ltd. (NASDAQ: GRVY), officially launched its mobile MMORPG game Ragnarok M: Eternal Love in Europe and Russian regions on October 16th. Ragnarok M: Eternal Love, which can be enjoyed in English, German, Spanish, French, Portuguese, and Russian, will truly become a game that can be played worldwide. To celebrate the global launch, Gravity prepared various events. (Graphic: Business Wire) To guarantee a stable service of the game, Gravity carried out a closed beta test from October 10th to October 13th. Following the examinations and server tests, the official service for Europe began on t
Comfy and Enlighted Collaborate to Create Smarter Workplaces17.10.2019 13:00:00 EEST | Press release
Comfy, the leading provider of global workplace experience solutions, and Enlighted, the leading provider of Internet of Things (IoT) solutions for commercial buildings, are partnering to deliver smarter workplaces. Their collaboration integrates Comfy’s powerful workplace experience platform with Enlighted’s award-winning building IoT technology. The first collaborative project is an intelligent desk reservation system addressing the growing need for open, activity-based workplaces. The solution features a new Enlighted desk sensor configuration and is currently being deployed across the global real estate portfolio of one of the world’s largest enterprise software companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005230/en/ Comfy and Enlighted have integrated their technologies to create a new intelligent desk reservation system. (Photo: Business Wire) Increasingly, companies are turning to unassigned seating
Logicalis Announces CEO Transition Plan17.10.2019 12:28:00 EEST | Press release
Logicalis, an international IT solution and managed services provider has announced that effective 1st March 2020, Mark Rogers will transition from his current CEO role to a Non-Executive Director (NED) role, at which point Robert Bailkoski will succeed Mark; Bob, currently COO, joined the company four years ago as CFO. Mark joined Logicalis 16 years ago and has spent the past 13 years in the pivotal roles of COO and CEO. During this period, the company experienced significant growth, with annual revenues increasing from $0.8bn to $1.7bn and EBITDA from $27m to $93m. In these roles, Mark has been extensively involved in M&A transactions and has overseen the integration of acquired businesses into the Logicalis Group, which expanded from a 9-country operation in 2007 to 26 countries today. Under his leadership, Logicalis has fostered a culture of professionalism, enthusiasm, and commitment in driving forward the importance and relevance of Logicalis for all its stakeholders while reposi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom